DV
Dividend Vision

JSPR — Jasper Therapeutics Inc

Jasper Therapeutics Inc (JSPR)

Total return is -99.2% over the past 6.6 years, 260.7 points behind SPY at 161.5%. Its deepest 1-year drawdown was 89.0%.

Jasper Therapeutics is a clinical-stage biotechnology company developing therapeutics for mast cell-driven diseases, with its lead product candidate being briquilimab, a monoclonal antibody targeting CD117 receptor signaling. The company does not currently distribute dividends. Jasper Therapeutics appeals primarily to investors seeking exposure to early-stage biotech development rather than current income generation.

JSPR key facts

Asset type
Stock
Asset class
Equity
Inception date
01/10/2020
Last close
$0.79
Market cap
$27,088,820
Average volume
568000.0
Beta
3.074
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.58